Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Person › Details

Paola Casarosa (Boehringer Ingelheim Innovation Unit)

Casarosa, Paola (Boehringer 202401– Managing Director Innovation Unit before Global Head Therapeutic Areas joined 2007)


Organisation Organisation Boehringer Ingelheim Innovation Unit
Products Product drug discovery
  Product 2 pharmaceutical

Boehringer Ingelheim. (12/20/22). "Press Release: Boehringer Ingelheim Announces Appointments to Board of Managing Directors". Ingelheim.

> Paola Casarosa appointed member of the Board of Managing.

> Directors per July 1, 2023, with responsibility for the Innovation Unit per January 1, 2024.

> Shashank Deshpande appointed member of the Board of Managing Directors per September 1, 2023, with responsibility for the Animal Health Business Unit per January 1, 2024.

> Michel Pairet and Jean Scheftsik de Szolnok to retire at the end of 2023.

Boehringer Ingelheim today announces that the Shareholders have appointed Paola Casarosa and Shashank Deshpande to the Board of Managing Directors. They will succeed Michel Pairet, responsible for the Innovation Unit, and Jean Scheftsik de Szolnok, responsible for the Animal Health Business Unit, who informed the Shareholders of their wish to retire at the end of next year.
Paola Casarosa Paola Casarosa - click on the photo for download

Paola Casarosa will succeed Michel Pairet to head the Innovation Unit. Paola joined Boehringer Ingelheim in 2007 and is currently Global Head of Therapeutic Areas in the Human Pharma Business Unit. Prior to this role, she held various leadership roles in Business Development and in Research. Paola is an Italian national, holds a PhD in Molecular Pharmacology and a Masters’ degree in Medicinal Chemistry.

Shashank Deshpande will succeed Jean Scheftsik de Szolnok to head the Animal Health Business Unit. Shashank joined Boehringer Ingelheim in 2012 and is currently Country Managing Director Japan. Prior to this role he held several leadership and marketing positions in Japan and Ingelheim. A German and US national, Shashank holds a Masters’ degree in Business Administration.

Christian Boehringer, Chairman of the Shareholders’ Committee said: “Our long-term planning allows for a seamless transition. On behalf of the Shareholders, I want to thank Michel and Jean for their many years of dedication to our company and I congratulate Paola and Shashank on their appointments.”

Hubertus von Baumbach, Chairman of the Board of Managing Directors, added: “I am grateful for the long time that I have had the privilege to work with Michel and Jean and I look forward to continuing to work with them until the end of 2023. The Board is excited to welcome Paola and Shashank to the team later next year.”

The appointment to the Board of Managing Directors will be effective July 1, 2023 for Paola Casarosa and September 1, 2023 for Shashank Deshpande.

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at

Media Contacts

Médard Schoenmaeckers
Head of Corporate Affairs
Phone Number: +49 (6132) 77-172784

Record changed: 2023-05-30


Picture Demy-Colton BioFuture 2024 NYC Reimagine Healthcare 650x200px

More documents for Paola Casarosa

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2024 NYC Game Changers 650x300px

» top